Announced
Financials
Tags
Acquisition
Belgium
Biotechnology
Private
Friendly
biotechnology company
Minority
Single Bidder
Private Equity
Pending
Synopsis
KKR & Co agreed to invest €50m ($54m) in Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics. "KKR, through Gamma Biosciences, seeks to back innovative and impactful next-generation bioprocessing technologies, which is why we are excited to be investing in Univercells and its mission to deliver affordable biologics and gene therapies globally. Furthermore, we are excited to be working with Hugues and his team, who have a fantastic track record of building innovative biomanufacturing companies," Kugan Sathiyanandarajah, KKR Director and Head of Europe for Health Care Strategic Growth.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.